This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Isis Initiates Phase 2 Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery

Stocks in this article: ISIS





CARLSBAD, Calif., Oct. 29, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 comparator-controlled study evaluating ISIS-FXI Rx in patients undergoing knee replacement surgery, also referred to as total knee arthroplasty (TKA).  ISIS-FXI Rx inhibits the production of Factor XI, a coagulation factor produced in the liver that is involved in the formation of clots.  In this study, Isis will evaluate the effectiveness of ISIS-FXI Rx in reducing the number of thrombotic events in patients after TKA without increasing bleeding.  The combination of robust anti-thrombotic activity with an improved safety profile to currently available anticoagulants could be broadly useful in many therapeutic settings where thrombosis is a serious problem.

"Although there are a number of anti-coagulants on the market today that are considered standard-of-care in multiple therapeutic settings, complications of bleeding associated with these medications remain high and can lead to fatal outcomes," said Harry Buller, Ph.D., M.D., professor of medicine at Academic Medical Center in Netherlands.  "Factor XI is an exciting target because it plays a key role in the formation of clots but inhibiting it does not cause bleeding.  Humans who are deficient in Factor XI tend to have a lower incidence of stroke and venous thrombosis with no evidence of spontaneous bleeding episodes."

The Phase 2 study is a global, multi-center, open-label, comparator-controlled study in up to 400 patients who are undergoing TKA.  The study will compare ISIS-FXI Rx safety and activity to enoxaparin, a commonly used anti-coagulant.  In a Phase 1 study in healthy volunteers, ISIS-FXI Rx produced robust dose-dependent, statistically significant reduction of greater than 80 percent in Factor XI activity with no bleeding events observed. 

"ISIS-FXI Rx is one of many maturing drugs in our pipeline and represents the broad applicability of our technology to develop novel drugs for many different diseases.  We believe that the safety profile observed thus far coupled with the robust activity we have seen for ISIS-FXI Rx in both our Phase 1 study and preclinically, suggest that this drug could have a significant benefit for patients at risk of a thrombotic event.  Given the mechanism of Factor XI inhibition, we believe that the drug could be used broadly to prevent deep vein thrombosis or pulmonary embolism in many different therapeutic settings, including stroke, myocardial infarction and with surgeries such as knee or hip replacement, where additional safe and effective anti-thrombotic drugs are needed.  Our earlier work suggests that ISIS-FXI Rx could be used in combination with existing therapies," said Sanjay Bhanot, M.D., Ph.D., vice president, clinical development and translational medicine at Isis. 

"TKA is one of the leading surgeries performed worldwide each year and is associated with a high incidence of venous thromboembolism," said Brett Monia, Ph.D., senior vice president, antisense drug discovery at Isis.  "By evaluating our drug in these patients, we will be able to directly compare the activity and safety of ISIS-FXI Rx to a commonly prescribed anti-coagulant, enoxaparin.  With this proof-of-value data in hand, we believe that we will have a robust and comprehensive data package representing a significant licensing opportunity for us."



1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs